binimetinib/encorafenib
Jump to navigation
Jump to search
Introduction
FDA approved June 2018
Indications
- treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma
Dosage
- binimetini 15 mg, encorafenib 50-75 mg PO
Adverse effects
- increased serum GGT
- increased serum creatine kinase
- hypertension
Mechanism of action
- selective inhibitor of MEK (binimetini)
- BRAF inhibitor (encorafenib)
More general terms
Components
References
- ↑ FDA DRug Approvals. June 27, 2018 FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm611981.htm
- ↑ Dummer R, Ascierto PA, Gogas HJ et al Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):603-615. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29573941